Scisparc Ltd (SPRC)

Apr 25, 2025, 7:59 AM EDT - 1 day ago

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

CMND

Mar 3, 2025, 8:25 AM EST - 7 weeks ago

SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers

Feb 27, 2025, 8:45 AM EST - 2 months ago

SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax's Entry into Direct Import of JAC Electric Vehicles

Feb 18, 2025, 7:17 AM EST - 2 months ago

SciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology

Feb 4, 2025, 9:00 AM EST - 2 months ago

SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico

Jan 15, 2025, 7:34 AM EST - 3 months ago

SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

Jan 13, 2025, 8:41 AM EST - 3 months ago

SciSparc: AutoMax Enters the Direct Import Market with a $13 Million First Shipment of JAC Electric Vehicles

Jan 7, 2025, 7:25 AM EST - 3 months ago

SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results

Jan 6, 2025, 11:04 AM EST - 3 months ago

Why Is Psychedelic-SciSparc Stock Trading Higher On Monday?

Jan 6, 2025, 7:50 AM EST - 3 months ago

SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment

Dec 31, 2024, 9:24 AM EST - 4 months ago

SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder

Dec 26, 2024, 2:36 PM EST - 4 months ago

S&P 500 Edges Lower, SciSparc Shares Surge

Dec 26, 2024, 6:46 AM EST - 4 months ago

SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation

Dec 16, 2024, 7:40 AM EST - 4 months ago

SciSparc Provides Updates on Status of Spin-off of its Advanced Clinical Stage Pharmaceutical Portfolio to a Publicly Traded Company

Sep 30, 2024, 9:25 AM EDT - 7 months ago

SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment

Sep 26, 2024, 9:05 AM EDT - 7 months ago

SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX

Sep 23, 2024, 8:17 AM EDT - 7 months ago

SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment

Sep 18, 2024, 4:09 PM EDT - 7 months ago

SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment

Sep 16, 2024, 4:06 PM EDT - 7 months ago

SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy

Sep 11, 2024, 7:40 AM EDT - 8 months ago

SciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax's Direct Import Agreement with Major Chinese Vehicle Manufacturer

Sep 6, 2024, 7:55 AM EDT - 8 months ago

SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment

Aug 29, 2024, 4:25 PM EDT - 8 months ago

SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination

Aug 28, 2024, 8:55 AM EDT - 8 months ago

SciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million

Aug 23, 2024, 4:09 PM EDT - 8 months ago

SciSparc Submitted IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients with Tourette Syndrome

Aug 22, 2024, 8:12 AM EDT - 8 months ago

SciSparc: MitoCareX Appointed Professor Nir Peled, Seasoned Oncologist, to its Scientific Advisory Board

Aug 19, 2024, 4:11 PM EDT - 8 months ago

SciSparc Announces Enrollment of the First Five Patients in the Clinical Trial of its Innovative SCI-210 Treatment

Aug 19, 2024, 7:51 AM EDT - 8 months ago

Israeli Penny Stock Biotech SciSparc Outlicenses Its Cannabinoid Pain Therapy

Aug 16, 2024, 4:30 PM EDT - 9 months ago

SciSparc Finalizes Exclusive Global Out-Licensing Agreement for its Pain Therapy Valued at $3 million

Aug 14, 2024, 4:53 PM EDT - 9 months ago

SciSparc Updates Regarding the Status of the AutoMax Merger

Aug 6, 2024, 8:57 AM EDT - 9 months ago

SciSparc's Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug

Jul 22, 2024, 8:20 AM EDT - 9 months ago

SciSparc: MitoCareX Confirms Potential Significant Role of its Drug Target in Non-Small Cell Lung Cancer

Jul 17, 2024, 7:07 AM EDT - 10 months ago

SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million

Jul 16, 2024, 11:55 AM EDT - 10 months ago

SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification

Jul 16, 2024, 6:03 AM EDT - 10 months ago

SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss

Jul 8, 2024, 8:30 AM EDT - 10 months ago

SciSparc Signs Non-Binding Letter of Intent for Spin Off of Advanced Clinical Stage Pharmaceutical Portfolio to Publicly Traded Company

May 31, 2024, 7:17 AM EDT - 11 months ago

SciSparc Secures Strategic Advantage with Grant of European Patent

May 21, 2024, 9:26 AM EDT - 1 year ago

Action Alliance Research: Family, Friends Need More Resources and Support to Help Loved Ones Who Are Struggling with Their Mental Health

Apr 11, 2024, 8:15 AM EDT - 1 year ago

SciSparc to Acquire AutoMax

Mar 27, 2024, 8:55 AM EDT - 1 year ago

SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression

Mar 21, 2024, 8:58 AM EDT - 1 year ago

SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Research

Mar 18, 2024, 7:29 AM EDT - 1 year ago

SciSparc Granted Another Patent, Strengthening its Core Technology in Canada

Mar 14, 2024, 8:49 AM EDT - 1 year ago

SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial

Mar 12, 2024, 8:14 AM EDT - 1 year ago

SciSparc: MitoCareX Reveals Promising Results with Discovery of Novel Anti-Cancer Small Molecule Structure

Mar 8, 2024, 7:11 AM EST - 1 year ago

SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorder

Mar 7, 2024, 7:49 AM EST - 1 year ago

SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe

Mar 6, 2024, 4:41 PM EST - 1 year ago

SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology

Feb 29, 2024, 8:35 AM EST - 1 year ago

SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing

Feb 27, 2024, 7:58 AM EST - 1 year ago

SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds

Feb 20, 2024, 7:14 AM EST - 1 year ago

SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds

Jan 29, 2024, 7:18 AM EST - 1 year ago

SciSparc Announces Initiation of Patient Recruitment for its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder